NovaBiotics Ltd is a clinical-stage speciality biotechnology company focused on the application of first-in-class anti-infective technology for difficult-to-treat, medically unmet fungal and bacterial conditions.
As a leading innovator in the anti-infectives space, NovaBiotics' business model is to develop candidate therapeutics to early/mid clinical stage prior to further development of product candidates and technology platform with commercialisation, out-licensing or co-development partners thereafter. This model has been validated with the recent signing of a licence and co development agreement with Taro Pharmaceuticals North America Inc. for its lead product Novexatin®.
Using informed, rational drug design principles versus high-risk screening strategies, the company has developed an exciting pipeline of products utilising this streamlined process to deliver them to clinic in less than 5 years from patent priority dates.
Founded in Aberdeen by Dr. Deborah O'Neil in 2004, the Company has a wealth of expertise in the biotechnology and pharmaceutical sector and the team Deborah has built (comprising immunology, microbiology and antimicrobial peptide expertise) provides the Company with all the sector-specific skills to continue its unrivalled anti-infective business development.
Further information on NovaBiotics Ltd is available at: http://www.novabiotics.co.uk
“The Townsend family first invested in NovaBiotics in 2006 and has continued to support the company as a major cornerstone funder, both through further investments and by introducing other ‘High Net Worth’ individuals. This has been key in enabling NovaBiotics to successfully develop the company’s lead compound, Novexatin®, a first-in-class antifungal peptide treatment for fungal nail infections.
Without the belief and support of our shareholders, Novexatin® and our exciting pipeline would not be where it is today”.
Dr. Deborah O’Neil, CEO & CSO, Founder – NovaBiotics Ltd